KANT Stock Overview
A clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Kineta, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.60 |
| 52 Week High | US$4.16 |
| 52 Week Low | US$0.26 |
| Beta | 0 |
| 1 Month Change | 0.93% |
| 3 Month Change | -28.11% |
| 1 Year Change | -84.56% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -84.11% |
Recent News & Updates
Recent updates
Shareholder Returns
| KANT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.3% | -4.2% | -0.9% |
| 1Y | -84.6% | 3.0% | 27.6% |
Return vs Industry: KANT underperformed the US Biotechs industry which returned 3% over the past year.
Return vs Market: KANT underperformed the US Market which returned 27.6% over the past year.
Price Volatility
| KANT volatility | |
|---|---|
| KANT Average Weekly Movement | 26.0% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: KANT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: KANT's weekly volatility (26%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 12 | n/a | kinetabio.com |
Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug.
Kineta, Inc. Fundamentals Summary
| KANT fundamental statistics | |
|---|---|
| Market cap | US$9.31m |
| Earnings (TTM) | -US$17.28m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs KANT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KANT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$9.02m |
| Gross Profit | -US$9.02m |
| Other Expenses | US$8.26m |
| Earnings | -US$17.28m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.41 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -6.6% |
How did KANT perform over the long term?
See historical performance and comparison